Histopathological features of breast cancer in carriers of ATM gene variants

Histopathology

Volumn 49, Issue 5, 2006, Pages 523-532

  Balleine, R L ^a,e,f,i   Murali, R ^d   Bilous, A M ^d,f   Farshid, G ^g   Waring, P ^h   Provan, P ^a,e   Byth, K ^c   Thorne, H ^h   Kirk, J A ^b,e,f  

^a Western Sydney Local Health Network   (Australia)

^b Familial Cancer Service   (Australia)

^c Division of Medicine   (United States)

^d SYDNEY SOUTH WEST AREA HEALTH SERVICE   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^h PETER MACCALLUM CANCER CENTRE   (Australia)

ⁱ WESTMEAD HOSPITAL   (Australia)

Author keywords

ATM; Breast cancer; Pathology

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER FAMILY; CANCER GENETICS; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; FEMALE; GENE MUTATION; GENETIC VARIABILITY; HETEROZYGOSITY; HISTOPATHOLOGY; HUMAN; PHENOTYPE; PRIORITY JOURNAL;

ATAXIA TELANGIECTASIA;

EID: 33750331445     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2006.02538.x     Document Type: Article

References (42)

1. Tracey EA, Roder D, Bishop J, Chen S, Chen W. Breast cancer. In Cancer in New South Wales: incidence and mortality 2003. Sydney: Cancer Institute NSW 2005; 60.
2. Thompson D, Easton D. The genetic epidemiology of breast cancer genes. J. Mammary Gland Biol. Neoplasia 2004; 9; 221-236.
3. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am. J. Hum. Genet. 1998; 62; 676-689.
4. Vaziri SAJ, Krumroy LM, Elson P et al. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin. Cancer Res. 2001; 7; 1937-1945.
5. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997; 349; 1505-1510.
6. Lakhani SR, Jacquemier J, Sloane JP et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl Cancer Inst. 1998; 90; 1138-1145.
7. Lakhani SR, Van De Vijver MJ, Jacquemier J et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J. Clin. Oncol. 2002; 20; 2310-2318.
8. Foulkes WD, Stefansson IM, Chappuis PO et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl Cancer Inst. 2003; 95; 1482-1485.
9. Lakhani SR, Reis-Filho JS, Fulford L et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin. Cancer Res. 2005; 11; 5175-5180.
10. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer 2004; 4; 665-676.
11. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002; 108; 171-182.
12. Foulkes WD. BRCA1 functions as a breast stem cell regulator. J. Med. Genet. 2004; 41; 1-5.
13. McKinnon PJ. ATM and ataxia telangiectasia. EMBO Reports 2004; 5; 772-776.
14. Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N. Engl. J. Med. 1987; 316; 1289-1294.
15. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N. Engl. J. Med. 1991; 325; 1831-1836.
16. Khanna KK, Chenevix-Trench G. ATM and genome maintenance: defining its role in breast cancer susceptibility. J. Mammary Gland Biol. Neoplasia 2004; 9; 247-262.
17. Gatti RA, Tward A, Concannon P. Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. Mol. Genet. Metab. 1999; 68; 419-423.
18. Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer. Available at http://www.kconfab.org. Last accessed September 2006.
19. National Health and Medical Research Council. Clinical Practice Guidelines. Familial aspects of cancer: a guide to clinical practice. 1999 Commonwealth of Australia, Canberra; 53.
20. Chenevix-Trench G, Spurdle AB, Gatei M et al. Dominant negative ATM mutations in breast cancer families. J. Natl Cancer Inst. 2002; 94; 205-215 [erratum appears in J. Natl Cancer Inst. 2002; 94; 952].
21. Thompson D, Antoniou AC, Jenkins M et al. Two ATM variants and breast cancer risk. Hum. Mutation 2005; 25; 594-595.
22. Thorstenson YR, Roxas A, Kroiss R et al. Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res. 2003; 63; 3325-3333.
23. Fisher CJ, Egan MK, Smith P et al. Histopathology of breast cancer in relation to age. Br. J. Cancer 1997; 75; 593-596.
24. Cowan WK, Kelly P, Sawan A et al. The pathological and biological nature of screen-detected breast carcinomas: a morphological and immunohistochemical study. J. Pathol. 1997; 182; 29-35.
25. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19; 403-410.
26. Eisinger F, Stoppa-Lyonnet D, Longy M et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res. 1996; 56; 471-474.
27. Eisinger F, Jacquemier J, Charpin C et al. Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res. 1998; 58; 1588-1592.
28. Armes JE, Egan AJM, Southey MC et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 1998; 83; 2335-2345.
29. Lynch BJ, Holden JA, Buys SS, Neuhausen SL, Gaffney DK. Pathobiologic characteristics of hereditary breast cancer. Hum. Pathol. 1998; 29; 1140-1144.
30. Chang J, Hilsenbeck SG, Sng JH, Wong J, Ragu GC. Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients. Clin. Cancer Res. 2001; 7; 1739-1742.
31. Abd El-Rehim DM, Pinder SE, Paish CE et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J. Pathol. 2004; 203; 661-671.
32. Livasy CA, Karaca G, Nanda R. et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod. Pathol. 2006; 19; 264-271.
33. Bilous M, Ades C, Armes J et al. Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study. Breast 2003; 12; 92-98.
34. Lakhani SR, Gusterson BA, Jacquemier J et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin. Cancer Res. 2000; 6; 782-789.
35. Broeks A, Urbanus JHM, Floore AN et al. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am. J. Hum. Genet. 2000; 66; 494-500.
36. Lindeman GJ, Hiew M, Visvader JE et al. Frequency of the ATM IVS10-6T->G variant in Australian multiple-case breast cancer families. Breast Cancer Res. 2004; 6; R401-R407.
37. Stankovic T, Kidd AMJ, Sutcliffe A et al. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am. J. Hum. Genet. 1998; 62; 334-345.
38. Bernstein JL, Bernstein L, Thompson WD et al. ATM variants 7271T>G and IVS10-6T>G among women with unilateral and bilateral breast cancer. Br. J. Cancer 2003; 89; 1513-1516.
39. Szabo CI, Schutte M, Broeks A et al. Are ATM mutations 7271T->G and IVS10-6T->G really high-risk breast cancer-susceptibility alleles? Cancer Res. 2004; 64; 840-843.
40. Thompson D, Duedal S, Kirner J et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J. Natl Cancer Inst. 2005; 97; 813-822.
41. Cavaciuti E, Lauge A, Janin N et al. Cancer risk according to type and location of ATM mutation in ataxia-telangiectasia families. Genes Chromosomes Cancer 2005; 42; 1-9.
42. Bowen TJ, Yakushiji H, Montagna C et al. Atm heterozygosity cooperates with loss of Brca1 to increase severity of mammary gland cancer and reduce ductal branching. Cancer Res. 2005; 65; 8736-8746.